ANI Free Cash Flow vs End Period Cash Flow Analysis

ANIP Stock

USD 56.91 1.05 1.88%

ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Free Cash Flow and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Free Cash Flow vs End Period Cash Flow

Free Cash Flow vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Free Cash Flow account and End Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between ANI Pharmaceuticals' Free Cash Flow and End Period Cash Flow is 0.66. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Free Cash Flow and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of ANI Pharmaceuticals are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Free Cash Flow i.e., ANI Pharmaceuticals' Free Cash Flow and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.66

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

End Period Cash Flow

Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.At this time, ANI Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 11/23/2024, Enterprise Value Over EBITDA is likely to grow to 10.15, while Issuance Of Capital Stock is likely to drop slightly above 71.8 M.

ANI Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Stockholder Equity	Short Long Term Debt Total	Short Term Debt	Current Deferred Revenue	Non Currrent Assets Other	Non Current Liabilities Total	Net Receivables	Net Tangible Assets
Total Assets		0.95	0.84	1.0	0.9	0.59	0.16	0.94	0.6	0.95	0.6	-0.48	0.93	0.61	0.99	0.96	0.95	-0.48	0.98	0.84	-0.18	0.61	0.68	0.91	0.97	0.09
Other Current Liab	0.95		0.88	0.95	0.87	0.48	0.06	0.97	0.6	0.86	0.6	-0.38	0.85	0.66	0.93	0.95	0.93	-0.38	0.94	0.71	-0.22	0.54	0.69	0.82	0.96	0.14
Total Current Liabilities	0.84	0.88		0.83	0.86	0.55	0.16	0.81	0.43	0.82	0.43	-0.37	0.77	0.51	0.84	0.85	0.77	-0.37	0.79	0.68	-0.05	0.36	0.52	0.62	0.83	-0.09
Total Stockholder Equity	1.0	0.95	0.83		0.88	0.52	0.15	0.94	0.66	0.92	0.66	-0.48	0.93	0.62	0.98	0.95	0.96	-0.48	0.99	0.82	-0.14	0.64	0.72	0.9	0.95	0.15
Property Plant And Equipment Net	0.9	0.87	0.86	0.88		0.76	0.26	0.83	0.32	0.95	0.32	-0.48	0.79	0.5	0.93	0.94	0.76	-0.48	0.85	0.86	-0.25	0.25	0.37	0.81	0.91	-0.09
Net Debt	0.59	0.48	0.55	0.52	0.76		0.34	0.44	-0.26	0.81	-0.26	-0.44	0.51	0.23	0.66	0.64	0.3	-0.44	0.51	0.78	-0.21	0.06	-0.03	0.6	0.65	-0.5
Retained Earnings	0.16	0.06	0.16	0.15	0.26	0.34		-0.06	-0.04	0.27	-0.04	-0.89	0.3	-0.07	0.18	0.08	0.04	-0.89	0.18	0.36	0.4	0.08	0.09	0.03	0.09	-0.18
Accounts Payable	0.94	0.97	0.81	0.94	0.83	0.44	-0.06		0.62	0.83	0.62	-0.31	0.8	0.74	0.92	0.96	0.94	-0.31	0.93	0.7	-0.38	0.56	0.67	0.87	0.96	0.22
Cash	0.6	0.6	0.43	0.66	0.32	-0.26	-0.04	0.62		0.34	1.0	-0.19	0.63	0.37	0.53	0.47	0.81	-0.19	0.65	0.28	0.11	0.68	0.79	0.48	0.47	0.61
Non Current Assets Total	0.95	0.86	0.82	0.92	0.95	0.81	0.27	0.83	0.34		0.34	-0.52	0.86	0.5	0.97	0.93	0.79	-0.52	0.9	0.9	-0.18	0.44	0.48	0.88	0.93	-0.16
Cash And Short Term Investments	0.6	0.6	0.43	0.66	0.32	-0.26	-0.04	0.62	1.0	0.34		-0.19	0.63	0.37	0.53	0.47	0.81	-0.19	0.65	0.28	0.11	0.68	0.79	0.48	0.47	0.61
Common Stock Total Equity	-0.48	-0.38	-0.37	-0.48	-0.48	-0.44	-0.89	-0.31	-0.19	-0.52	-0.19		-0.57	-0.35	-0.48	-0.41	-0.39	1.0	-0.53	-0.6	-0.22	-0.37	-0.38	-0.39	-0.43	0.01
Common Stock Shares Outstanding	0.93	0.85	0.77	0.93	0.79	0.51	0.3	0.8	0.63	0.86	0.63	-0.57		0.54	0.91	0.82	0.89	-0.57	0.93	0.81	0.09	0.72	0.72	0.83	0.85	0.11
Other Current Assets	0.61	0.66	0.51	0.62	0.5	0.23	-0.07	0.74	0.37	0.5	0.37	-0.35	0.54		0.57	0.66	0.65	-0.35	0.7	0.53	-0.41	0.46	0.62	0.67	0.69	0.21
Total Liab	0.99	0.93	0.84	0.98	0.93	0.66	0.18	0.92	0.53	0.97	0.53	-0.48	0.91	0.57		0.97	0.91	-0.48	0.97	0.87	-0.21	0.56	0.61	0.91	0.97	0.04
Property Plant And Equipment Gross	0.96	0.95	0.85	0.95	0.94	0.64	0.08	0.96	0.47	0.93	0.47	-0.41	0.82	0.66	0.97		0.89	-0.41	0.94	0.83	-0.34	0.44	0.53	0.9	0.98	0.08
Total Current Assets	0.95	0.93	0.77	0.96	0.76	0.3	0.04	0.94	0.81	0.79	0.81	-0.39	0.89	0.65	0.91	0.89		-0.39	0.96	0.69	-0.16	0.71	0.79	0.85	0.9	0.34
Common Stock	-0.48	-0.38	-0.37	-0.48	-0.48	-0.44	-0.89	-0.31	-0.19	-0.52	-0.19	1.0	-0.57	-0.35	-0.48	-0.41	-0.39		-0.53	-0.6	-0.22	-0.37	-0.38	-0.39	-0.43	0.01
Other Stockholder Equity	0.98	0.94	0.79	0.99	0.85	0.51	0.18	0.93	0.65	0.9	0.65	-0.53	0.93	0.7	0.97	0.94	0.96	-0.53		0.83	-0.16	0.67	0.74	0.92	0.95	0.18
Short Long Term Debt Total	0.84	0.71	0.68	0.82	0.86	0.78	0.36	0.7	0.28	0.9	0.28	-0.6	0.81	0.53	0.87	0.83	0.69	-0.6	0.83		-0.13	0.39	0.39	0.83	0.82	-0.09
Short Term Debt	-0.18	-0.22	-0.05	-0.14	-0.25	-0.21	0.4	-0.38	0.11	-0.18	0.11	-0.22	0.09	-0.41	-0.21	-0.34	-0.16	-0.22	-0.16	-0.13		0.14	-0.02	-0.37	-0.33	0.13
Current Deferred Revenue	0.61	0.54	0.36	0.64	0.25	0.06	0.08	0.56	0.68	0.44	0.68	-0.37	0.72	0.46	0.56	0.44	0.71	-0.37	0.67	0.39	0.14		0.83	0.55	0.55	0.28
Non Currrent Assets Other	0.68	0.69	0.52	0.72	0.37	-0.03	0.09	0.67	0.79	0.48	0.79	-0.38	0.72	0.62	0.61	0.53	0.79	-0.38	0.74	0.39	-0.02	0.83		0.58	0.6	0.18
Non Current Liabilities Total	0.91	0.82	0.62	0.9	0.81	0.6	0.03	0.87	0.48	0.88	0.48	-0.39	0.83	0.67	0.91	0.9	0.85	-0.39	0.92	0.83	-0.37	0.55	0.58		0.91	0.09
Net Receivables	0.97	0.96	0.83	0.95	0.91	0.65	0.09	0.96	0.47	0.93	0.47	-0.43	0.85	0.69	0.97	0.98	0.9	-0.43	0.95	0.82	-0.33	0.55	0.6	0.91		0.06
Net Tangible Assets	0.09	0.14	-0.09	0.15	-0.09	-0.5	-0.18	0.22	0.61	-0.16	0.61	0.01	0.11	0.21	0.04	0.08	0.34	0.01	0.18	-0.09	0.13	0.28	0.18	0.09	0.06

Click cells to compare fundamentals

ANI Pharmaceuticals Account Relationship Matchups

ANI Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Liab	36.7M	50.1M	60.0M	65.5M	98.2M	103.1M
Total Current Liabilities	61.7M	78.6M	87.5M	99.4M	145.5M	152.8M
Total Stockholder Equity	212.8M	195.7M	358.7M	338.5M	432.7M	454.4M
Property Plant And Equipment Net	40.6M	41.3M	52.7M	43.2M	44.6M	46.8M
Net Debt	123.4M	177.8M	187.1M	238.3M	64.5M	38.9M
Retained Earnings	17.6M	(5.0M)	(47.8M)	(97.3M)	(80.1M)	(84.1M)
Accounts Payable	14.6M	11.3M	23.0M	29.3M	36.7M	38.5M
Cash	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Non Current Assets Total	269.1M	290.9M	449.8M	415.8M	384.6M	403.8M
Cash And Short Term Investments	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Common Stock Shares Outstanding	12.0M	12.0M	12.6M	16.3M	18.2M	19.1M
Liabilities And Stockholders Equity	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Assets	5.1M	5.9M	11.3M	25.2M	25.4M	26.7M
Total Liab	244.0M	265.5M	412.9M	421.5M	446.8M	469.2M
Property Plant And Equipment Gross	40.6M	41.3M	75.6M	76.0M	77.5M	81.4M
Total Current Assets	187.7M	170.3M	321.8M	344.3M	519.8M	545.8M
Other Stockholder Equity	200.1M	212.1M	384.7M	398.8M	479.2M	503.1M
Accumulated Other Comprehensive Income	(4.9M)	(11.4M)	(3.1M)	12.2M	8.9M	9.3M
Short Long Term Debt Total	185.7M	185.7M	287.4M	286.5M	285.7M	148.2M
Short Term Debt	115.7M	9.9M	13.2M	850K	2.4M	2.3M
Current Deferred Revenue	451K	80K	87K	32.5M	37.4M	39.2M
Non Currrent Assets Other	1.2M	802K	2.2M	2.6M	12.1M	12.7M
Non Current Liabilities Total	182.3M	186.9M	325.3M	322.1M	301.3M	316.4M
Net Receivables	72.1M	95.8M	128.5M	165.4M	162.1M	170.2M
Net Tangible Assets	28.8M	3.6M	36.7M	58.7M	52.8M	55.5M
Other Assets	44.6M	57.5M	75.1M	92.7M	106.6M	112.0M
Long Term Debt	175.8M	172.4M	286.5M	285.7M	284.8M	149.2M
Retained Earnings Total Equity	17.6M	(5.0M)	(47.8M)	(97.3M)	(111.9M)	(117.5M)
Inventory	48.2M	60.8M	81.7M	105.4M	111.2M	116.8M
Deferred Long Term Liab	1.5M	800K	500K	600K	690K	458.1K
Intangible Assets	180.4M	188.5M	294.1M	251.6M	209.0M	156.5M
Property Plant Equipment	40.6M	41.3M	52.7M	43.2M	49.7M	52.2M
Capital Surpluse	200.8M	214.4M	387.8M	403.9M	464.5M	237.5M
Other Liab	7K	201K	31.0M	35.1M	40.3M	42.3M

Pair Trading with ANI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against ANI Stock

0.38	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.35	VRDN	Viridian Therapeutics	Pair Corr
0.31	GILD	Gilead Sciences	Pair Corr

The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.

The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC